Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 34 current clinical trials in our China register. 19 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Clopidogrel, Dezocine and Spironolactone. The most-studied condition is Hyperaldosteronism.

ClinicalTrials.gov trials by status

Recruiting1956%
Not yet open1029%
Active, closed515%

Trials by phase

Observational1853%
Not applicable1235%
Phase 439%
Phase EARLY_PHASE113%

Clinical trials sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital

34 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Effect of Gut Microbiome Intervention on Aging Via Oral FMT NCT05598112 · ClinicalTrials.gov ↗ · Aging, Frailty	Phase EARLY_PHASE1	Recruiting	2023-04	China
CHina Adrenal Venous saMPling InvestigatiON NCT07252284 · ClinicalTrials.gov ↗ · Hyperaldosteronism, Adrenal Venous Sampling, Adrenalectomy	Observational	Recruiting	2025-05	China
The Application of T1 Mapping in Real-World NCT07354646 · ClinicalTrials.gov ↗ · Myocardial Infarction (MI), Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM)	Observational	Recruiting	2020-03	China
Cardiac Magnetic Resonance for Risk Stratification in Non-dilated Left Ventricular Cardiomyopathy NCT07351838 · ClinicalTrials.gov ↗ · Non-ischemic Cardiomyopathy	Observational	Recruiting	2010-01	China
Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques NCT07336394 · ClinicalTrials.gov ↗ · Danon Disease, Fabry Disease, Cardiac Amyloidosis	Observational	Recruiting	2010-01	China
Cardiac Normal Values Assessed by Magnetic Resonance Imaging NCT05346094 · ClinicalTrials.gov ↗ · Healthy Participants, Reference Values	Observational	Recruiting	2022-01	China
Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism NCT07328230 · ClinicalTrials.gov ↗ · Idiopathic Hyperaldosteronism, Hyperaldosteronism Drug: Spironolactone	Not applicable	Recruiting	2022-08	China
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant NCT06901466 · ClinicalTrials.gov ↗ · Mitral Regurgitation Drug: Clopidogrel	Phase 4	Recruiting	2025-06	China
Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF NCT04603404 · ClinicalTrials.gov ↗ · Heart Failure, Diastolic	Observational	Recruiting	2019-01	China
CMR Prognostic Markers in Ischemic Heart Disease NCT07351825 · ClinicalTrials.gov ↗ · Ischemic Heart Disease (IHD), Myocardial Infarction (MI)	Observational	Recruiting	2009-01	China
CMR-Based Prognostic Study in Patients With Cardiac Implantable Electronic Devices NCT07336225 · ClinicalTrials.gov ↗ · Arrhythmias	Observational	Recruiting	2010-01	China
Cardiac Magnetic Resonance for Risk Stratification in Dilated Cardiomyopathy NCT04990297 · ClinicalTrials.gov ↗ · Dilated Cardiomyopathy, Single-center Study	Observational	Recruiting	2019-12	China
Transaxillary TAVR With Solely Echocardiography Guidance NCT07035847 · ClinicalTrials.gov ↗ · Aortic Stenosis	Not applicable	Recruiting	2024-10	China
Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery NCT07048002 · ClinicalTrials.gov ↗ · Silent Brain Infarction, Neurocognitive Disorders, Cardiac Surgery	Not applicable	Recruiting	2025-07	China
Quantitative Superior Vena Cava Isolation in Addition to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation NCT05908955 · ClinicalTrials.gov ↗ · Atrial Fibrillation	Not applicable	Recruiting	2024-03	China
Time to Ambulation After ProGlide Closure NCT07179536 · ClinicalTrials.gov ↗ · Femoral Access Site Closure, Ambulation, Vascular Access Complication	Not applicable	Recruiting	2025-10	China
A Comparison of Biodegradable and Metal Occluders in Patients With PFO and Migraine NCT06203873 · ClinicalTrials.gov ↗ · PFO - Patent Foramen Ovale, Migraine, Migraine Headache	Not applicable	Recruiting	2024-03	China
Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging NCT04602338 · ClinicalTrials.gov ↗ · Heart Failure, Diastolic, Multicenter Study	Observational	Recruiting	2020-11	China
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant NCT07007143 · ClinicalTrials.gov ↗ · Mitral Regurgitation Drug: Clopidogrel	Phase 4	Recruiting	2025-07	China
China National Study of Adrenal Venous Sampling NCT06192238 · ClinicalTrials.gov ↗ · Hyperaldosteronism	Observational	Not yet open	2024-01	China
FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis NCT07511309 · ClinicalTrials.gov ↗ · Atherosclerotic Renal Artery Stenosis, Fractional Flow Reserve, Optimal Medical Therapy	Not applicable	Not yet open	2026-03	China
Perioperative Dezocine Administration and Postoperative Delirium in Elderly Cardiac Surgery Patients NCT07768150 · ClinicalTrials.gov ↗ · Postoperative Delirium (POD) Drug: Dezocine	Not applicable	Not yet open	2026-09	China
A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Valve Replacement for Type-0 Bicuspid Aortic Valve Stenosis Patients in China NCT07450196 · ClinicalTrials.gov ↗ · Aortic Stenosis, AORTIC VALVE DISEASES	Observational	Not yet open	2026-04	China
Effects of Remimazolam on Neurocognitive Function in Patients Undergoing Cardiovascular Surgery NCT07598019 · ClinicalTrials.gov ↗ · Neurocognitive Disorder, Cardiac Surgery	Observational	Not yet open	2026-06	China
A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire NCT07054541 · ClinicalTrials.gov ↗ · Atrial Septal Defect (ASD)	Phase 4	Not yet open	2026-03	China
Covered vs Bare Metal Stents for Atherosclerotic Renal Artery Stenosis NCT07566065 · ClinicalTrials.gov ↗ · Atherosclerotic Renal Artery Stenosis, Hypertension, Renal Artery Stenosis	Not applicable	Not yet open	2026-04	China
Cardiovascular Surgery Early Prediction System for AKI :CARDS-AKI Registry NCT07330453 · ClinicalTrials.gov ↗ · Cardiovascular Surgery	Observational	Not yet open	2025-12	China
A Clinical Trial of the Transcatheter Aortic Valve Implantation System With a Prospective, Multi-Center, One-Arm Approach to Evaluate the Efficacy and Safety in the Treatment of Patients With Severe Aortic Stenosis NCT05673525 · ClinicalTrials.gov ↗ · Aortic Stenosis	Not applicable	Not yet open	2022-12	China
TAVR for Aortic Regurgitation Under TEE Guidance NCT07453849 · ClinicalTrials.gov ↗ · Aortic Regurgitation, Transcatheter Aortic Valve Replacement	Not applicable	Not yet open	2026-03	China
Superior Vena Cava Isolation Plus Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation NCT06183619 · ClinicalTrials.gov ↗ · Atrial Fibrillation	Observational	Active, closed	2024-02	China
Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement NCT07390513 · ClinicalTrials.gov ↗ · Aortic Valve Stenosis, Arrhythmia	Observational	Active, closed	2022-01	China
Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population NCT05462262 · ClinicalTrials.gov ↗ · Coronary Artery Disease Progression	Not applicable	Active, closed	2022-10	China
Automated Reports Generation of Cardiovascular Magnetic Resonance Imaging NCT07340762 · ClinicalTrials.gov ↗ · HCM - Hypertrophic Cardiomyopathy	Observational	Active, closed	2025-10	China
Imaging Markers of High-Risk Plaque Phenotype for Predicting Post-PCI Outcomes NCT07117084 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Percutaneous Coronary Intervention (PCI), Atherosclerosis of Coronary Artery	Observational	Active, closed	2021-01	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Chinese Academy of Medical Sciences, Fuwai Hospital trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Clopidogrel2 Dezocine1 Spironolactone1

Conditions in Chinese Academy of Medical Sciences, Fuwai Hospital trials

58 conditions

Hyperaldosteronism3Aortic Stenosis3 Atrial Fibrillation2Myocardial Infarction (MI)2Atherosclerotic Renal Artery Stenosis2Mitral Regurgitation2Heart Failure, Diastolic2Cardiac Surgery2 Aging1 Frailty1Adrenal Venous Sampling1Adrenalectomy1Aortic Valve Stenosis1Arrhythmia1Hypertrophic Cardiomyopathy (HCM)1Dilated Cardiomyopathy (DCM)1Arrhythmogenic Cardiomyopathy1Fractional Flow Reserve1Optimal Medical Therapy1Stent Implantation1Non-ischemic Cardiomyopathy1Postoperative Delirium (POD)1Danon Disease1Fabry Disease1

By trial register

Register	Trials	Recruiting
Clinical trials in China	34	19

A trial with sites in more than one country appears in each of those registers.

Questions about Chinese Academy of Medical Sciences, Fuwai Hospital trials

How many clinical trials does Chinese Academy of Medical Sciences, Fuwai Hospital sponsor?

Chinese Academy of Medical Sciences, Fuwai Hospital is the lead sponsor of 34 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Chinese Academy of Medical Sciences, Fuwai Hospital trials recruiting?

Yes. 19 of its 34 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Chinese Academy of Medical Sciences, Fuwai Hospital testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are Clopidogrel (2), Dezocine (1) and Spironolactone (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Chinese Academy of Medical Sciences, Fuwai Hospital clinical trials